FDA Approves New Drug to Fight Chronic Migraines

A new drug designed to fight chronic migraine attacks could be on the market within a week.

The FDA approved Aimovig on Thursday.

It’s designed to reduce the frequency of migraines that affect about 12 percent of Americans.

The drug works by blocking the activity of a genetic molecule involved in migraine attacks.

Patients will be able to administer Aimovig through monthly injections at home.

The drug requires a prescription and it’s expected to come with a price tag of $575 a month.